机译:HPIV3 / RSV双重融合抑制剂的结构指导改进
Department of Chemistry University of Wisconsin Madison Wisconsin 53706 United States;
Department of Pediatrics Columbia University Medical Center New York 10032 United States Beijing Pediatric Research Institute Beijing Children's Hospital Capital Medical University Beijing 100045 China;
Department of Pediatrics and Center for Host—Pathogen Interaction Columbia University Medical Center New York 10032 United States Department of Experimental Medicine University of Campania 'Luigi Vanvitelli' Caserta 81100 Italy;
Department of Pediatrics Center for Host—Pathogen Interaction Department of Microbiology & Immunology and Department of Physiology & Cellular Biophysics Columbia University Medical Center New York 10032 United States;
机译:在人类RSV攻击研究中发现口腔呼吸道合胞病毒(RSV)融合抑制剂(GS-5806)和概念验证的临床证据
机译:牛呼吸道合胞病毒感染模型中呼吸道合胞病毒(RSV)融合抑制剂的抗病毒功效。
机译:病毒介导的细胞融合需要呼吸道合胞病毒(RSV)糖蛋白的N-连接聚糖成熟的证据:α-甘露糖苷酶抑制剂对RSV感染性的影响
机译:技术的双重性:ICT是业务流程改进的推动者和抑制者
机译:人副流感病毒(hPIV3)融合蛋白的调节。
机译:1958年。呼吸道合胞病毒(RSV)融合蛋白抑制剂JNJ-53718678(JNJ-8678)的抗病毒作用药代动力学(PK)和安全性在1b期研究中被RSV感染的细支气管炎婴儿53718678RSV1005
机译:双HPIV3 / RSV融合剂的结构引导改善
机译:针对裂谷热病毒的融合抑制肽抑制多种多样的病毒。